1-3 of 3
Michael Kunz
Close
Sort by
Journal Articles

Health-Related Quality of Life in Patients with Advanced-Stage Follicular Lymphoma Receiving Consolidation with 90 Y-Ibritumomab Tiuxetan (Zevalin®) of First Remission: Results from the Randomized Phase 3 First-Line Indolent Trial (FIT).

Kathleen Gondek, Sonalee Shah, Angelika Bischof-Delaloye, Ama Rohatiner, Gilles Salles, Barbara Putz, Michael Kunz, Anton Hagenbeek
Journal: Blood
Blood (2007) 110 (11): 3319.
https://doi.org/10.1182/blood.V110.11.3319.3319
Published: 2007
Journal Articles

Radioimmunotherapy with 90 Y-Ibritumomab Tiuxetan (Zevalin®) as Consolidation of First Remission in Patients with Advanced Stage Follicular Lymphoma: A ’Real-Time’ MBR RQ-PCR Analysis.

Lindsey Goff, Karin Summers, Sameena Iqbal, Jens Kuhlmann, Michael Kunz, Anton Hagenbeek, Andrew Lister, Ama Rohatiner
Journal: Blood
Blood (2007) 110 (11): 3412.
https://doi.org/10.1182/blood.V110.11.3412.3412
Published: 2007
Journal Articles

90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients.

Anton Hagenbeek, Angelika Bischof-Delaloye, John A. Radford, Ama Rohatiner, Gilles Salles, Achiel Van Hoof, Barbara Putz, Michael Kunz, Franck Morschhauser
Journal: Blood
Blood (2007) 110 (11): 643.
https://doi.org/10.1182/blood.V110.11.643.643
Published: 2007